Ascendis Pharma

Ascendis shoots higher on pivotal win

Shares in the company surge after its weekly growth hormone treatment proves superior to daily injections, raising broader hopes for Ascendis’s long-acting technology.

Takeover flurry aside, progress of recent biotech floats underwhelms

A run of acquisitions of recent biotech IPOs is great news for investors who backed these companies, but the reality is that a large majority of fledgling drug stocks are under water.

February 01, 2019

Upcoming events – Ascendis and Lilly hope for growth with pivotal data

Ascendis aims to hit the Heights, while Lilly hopes for success with Olumiant in eczema, a new indication for the troubled Jak inhibitor.

September 22, 2017

Ascendis’s growth spurt comes courtesy of Versartis

September 21, 2015

Versartis grows taller, but still a way to go

June 24, 2015

IPO slowdown could signal bubble trouble

June 12, 2015

Upcoming events: Data from Redhill in ulcers and Ascendis in growth deficiencies

April 13, 2015

Floats stumble in Q1 as bubble debate escalates

December 13, 2010

Somatropin safety review highlights lack of alternatives